NEXGEL, Inc. (NXGL)

NCM – Цена в реальном времени. Валюта: USD

0.52

+0.01 (1.01%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.51

-0.01 (-2.77%)

После закрытия: Jun 26, 2026, 7:42 PM EDT

04.06.2026

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 – 18, 2026, in Las Vegas, NV.

15.05.2026

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

13.05.2026

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL.

12.05.2026

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa.

06.05.2026

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Brian J.

21.04.2026

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

17.04.2026

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET.

Видео

No Data

There is no data to display

Пресс-релизы

13.05.2026

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

06.05.2026

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

17.04.2026

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

12.03.2026

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio

NEXGEL, Inc. (NXGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NEXGEL, Inc. (NXGL)

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Видео

No Data

Пресс-релизы

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Видео

No Data

Пресс-релизы

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Search stocks

NEXGEL, Inc. (NXGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NEXGEL, Inc. (NXGL)

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Видео

No Data

Пресс-релизы

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Видео

No Data

Пресс-релизы

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products